AI-driven Congruence Therapeutics gets $50M to stabilize misfolded proteins
Biotech startup Congruence Therapeutics is developing novel drugs that treat disease by stabilizing misfolded proteins. Key to the company’s approach is a computational platform that discovers and designs these small molecule stabilizers.